Pathological complete response to neoadjuvant pembrolizumab in a patient with metastatic cutaneous squamous cell carcinoma
J Eur Acad Dermatol Venereol
.
2023 Nov;37(11):e1318-e1320.
doi: 10.1111/jdv.19307.
Epub 2023 Jul 11.
Authors
Manon Blaise
1
,
Gilles Poissonnet
2
,
Nathalie Cardot-Leccia
3
,
Anne Sudaka
4
,
Marine Velin
1
,
Madleen Chassang
5
,
Micheline Razzouk-Cadet
6
,
Alexandra Picard-Gauci
1
,
Thierry Passeron
1
7
,
Henri Montaudié
1
7
Affiliations
1
Dermatology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
2
Cervico-facial Department, Institut Universitaire de la Face et du Cou, Nice, France.
3
Histopathology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
4
Histopathology Department, Centre Antoine Lacassagne, Nice, France.
5
Radiology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
6
Nuclear Medicine Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
7
INSERM U1065, C3M, Université Côte d'Azur, Nice, France.
PMID:
37415448
DOI:
10.1111/jdv.19307
No abstract available
Publication types
Letter
MeSH terms
Carcinoma, Squamous Cell* / drug therapy
Carcinoma, Squamous Cell* / pathology
Head and Neck Neoplasms*
Humans
Neoadjuvant Therapy
Skin Neoplasms* / drug therapy
Substances
pembrolizumab